You are sleepy in a way that sleeping does not fix
Narcolepsy is a neurological disorder of the sleep-wake cycle whose defining feature is excessive daytime sleepiness that more time in bed does not resolve. Diagnosis requires sleep testing, and a new class of medicine was approved in August 2026.
What narcolepsy is
Narcolepsy is a chronic neurological disorder of the sleep-wake cycle. Its defining feature is excessive daytime sleepiness that does not resolve with more time in bed. Type 1 involves cataplexy, a sudden loss of muscle tone triggered by emotion, and is associated with a deficiency of the signalling chemical orexin.
It is commonly mistaken for depression, for poor sleep habits, or simply for being tired, and the gap between first symptoms and diagnosis is frequently measured in years.
A new class of medicine was approved in August 2026
On 5 August 2026 the FDA approved Orzeyful (oveporexton) for narcolepsy type 1 in adults. It is the first approved orexin receptor 2 agonist, a class intended to act on the underlying orexin deficiency rather than only on individual symptoms. It is an oral tablet taken twice daily.
The approval rests on two 12-week randomised, double-blind, placebo-controlled studies in 273 adults with narcolepsy type 1. The AASM’s summary reports improved ability to stay awake against placebo, reduced cataplexy, and improvement in sleep paralysis, hallucinations and disrupted night-time sleep.
Reported common adverse effects are insomnia, increased urinary frequency, urinary urgency and increased saliva. It should not be combined with strong CYP3A inhibitors, and safety and effectiveness have not been established under 18 years of age.
It is not something you can be prescribed today. Oveporexton has been recommended for scheduling under the Controlled Substances Act, and it is not lawful to market until the DEA issues that scheduling decision. Anyone telling you otherwise is ahead of the paperwork.
What is actually available now
The established, approved options have not gone anywhere, and while oveporexton is unscheduled they remain the practical choice. Broadly, they divide into medicines aimed at daytime sleepiness and medicines that also address cataplexy:
- Modafinil and armodafinil, for excessive daytime sleepiness.
- Solriamfetol, for excessive daytime sleepiness.
- Pitolisant, for sleepiness and cataplexy. It is not a controlled substance.
- Sodium oxybate, low-sodium oxybate, and once-nightly sodium oxybate, for sleepiness and cataplexy.
- Older stimulants including methylphenidate and the amphetamines.
Which of these suits you depends on your type of narcolepsy, your other conditions, what you have already tried, and what you are willing to take. That is a conversation, not a menu.
What happens here
Diagnosis requires sleep testing rather than a questionnaire, and the testing for suspected narcolepsy is not the same as the testing for sleep apnea. Long-term management is the larger part of the work: this is a condition managed over years, with the same physician, rather than settled in one visit.
Falling asleep during the day, every day?
If it happens while you are driving, stop driving and call. That is the one symptom on this site we would ask you not to wait on.
Call (614) 898-9340Sources
- AASM, “FDA approves Orzeyful for narcolepsy type 1 in adults”, 6 August 2026. https://aasm.org/fda-approves-orzeyful-for-narcolepsy-type-1-in-adults/
- Project Sleep, narcolepsy treatments overview, 2026. https://project-sleep.com/narcolepsy-treatments/
- Journal of Sleep Research review of hypersomnolence, 2026. https://doi.org/10.1111/jsr.70118